Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
äŒæ¥ã³ãŒãIBO
äŒç€ŸåImpact Biomedical Inc
äžå Žæ¥Sep 16, 2024
æé«çµå¶è²¬ä»»è
ãCEOãHeuszel (Frank D)
åŸæ¥å¡æ°2
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Sep 16
æ¬ç€Ÿæåšå°1400 Broadfield Blvd.
éœåžHOUSTON
蚌åžååŒæNASDAQ OMX â NASDAQ Basic Amex
åœUnited States of America
éµäŸ¿çªå·77084
é»è©±çªå·15852321500
ãŠã§ããµã€ãhttps://www.impactbiomedinc.com/
äŒæ¥ã³ãŒãIBO
äžå Žæ¥Sep 16, 2024
æé«çµå¶è²¬ä»»è
ãCEOãHeuszel (Frank D)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã